OL 003
Alternative Names: OL-003Latest Information Update: 16 Dec 2022
At a glance
- Originator Oleolive
- Class Anti-inflammatories; Antidementias
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 16 Dec 2022 Preclinical trials in Alzheimer's disease in USA (IV), before December 2022 (Oleolive pipeline, December 2022)
- 16 Dec 2022 Preclinical trials in Alzheimer's disease in USA (PO), before December 2022 (Oleolive pipeline, December 2022)
- 16 Dec 2022 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical trial in Alzheimer's diseases released by Oleolive before December 2022 (Oleolive pipeline, December 2022)